An oral Janus kinase (JAK) inhibitor for the treatment of adults with moderately to severely active rheumatoid arthritis…
For the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+) previously treated chronic myelogenous leukemia…
Eliquis (apixaban) gained approval to reduce the risk of stroke and systemic embolism…
For the treatment of advanced kidney cancer when one prior drug treatment for this disease has not worked or has stopped working…
Quillivant XR(methylphenidate HCl)
The first once-daily liquid medication approved in the U.S. for the treatment of attention deficit/hyperactivity disorder…
Xeljanz (tofacitnib) is the first new oral disease-modifying antirheumatic drug approved for rheumatoid arthritis in more than 10 years and the first rheumatoid arthritis treatment in a new class of medicines known as Janus kinase (JAK) inhibitors. Unlike biologic therapies, which work outside the cell, Xeljanz targets the inflammation associated with rheumatoid arthritis from inside the cell. Specifically, Xeljanz inhibits the JAK pathways, which are signaling pathways inside cells that are used by pro-inflammatory cytokines (proteins that facilitate communication between cells). Approved in the U.S. for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, Xeljanz is currently under review by several regulatory agencies around the world, including in Europe and Japan.
Bosulif (bosutinib) is for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Once-daily Bosulif was studied in a broad range of patients with CML, including CML patients treated with imatinib followed by a second-generation tyrosine kinase inhibitor. Bosulif addresses an unmet need in the CML treatment landscape.
Eliquis (apixaban) gained approval to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation in the U.S., the 27 countries in the European Union, Canada, and Japan, and is under review in other countries. Elliquis, an oral Factor Xa inhibitor anticoagulant, has demonstrated superior risk reductions versus warfarin in three key outcomes of stroke and systemic embolism, major bleeding and all-cause death in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize this oral anticoaglulant discovered by Bristol-Myers Squibb.
Inlyta (axitinib) is indicated for the treatment of advanced kidney cancer when one prior drug treatment for this disease has not worked or has stopped working. It is the first treatment to demonstrate superior progression-free survival in a Phase III study compared with sorafenib in second-line advanced kidney cancer. Since its approval, Inlyta has established its utility in this setting, where it is an important treatment option for many patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, is the first once-daily liquid medication approved in the U.S. for the treatment of attention deficit/hyperactivity disorder (ADHD). This recently approved medicine is expected to be available in pharmacies in the U.S. in early 2013. With the acquisition of NextWave Pharmaceuticals in 2012, Pfizer gained exclusive North American rights to market Quillivant XR.